Additionally, GO analysis of those 1,132 marker genes with differentially modified 5hmC between DLBCL patients and healthy controls suggested enrichment in immune and inflammation-related signaling pathways, such as myeloid leukocyte activation, CD4-positive alpha-beta T cell activation, peptidyl-serine modification. Here, CD4 is linked to diffuse large B-cell lymphoma.